CLDX Stock Analysis: Celldex Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.407m USD | 12M Return: 7.9% | US15117B2025 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.7M
Qual. Beats: 0
Rev. Trend: -85.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Celldex Therapeutics is a US-based clinical-stage biopharmaceutical company that develops monoclonal and bispecific antibodies to treat severe inflammatory, allergic, and autoimmune diseases where existing therapies are inadequate. The companys pipeline is centered on mast cell–mediated conditions, with its lead candidate Barzolvolimab (CDX-0159), a KIT receptor–targeting monoclonal antibody being studied in chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis, alongside CDX-622, a bispecific antibody that neutralizes thymic stromal lymphopoietin (TSLP) while depleting mast cells via stem cell factor starvation. The company is headquartered in Hampton, New Jersey, and is classified within the GICS Biotechnology sub-industry.
As a pre-commercial biotech, Celldex operates a typical pipeline-driven business model in which value is tied to clinical-trial outcomes and regulatory progress rather than product sales, and its mid-cap market capitalization reflects investor expectations tied to the advancement of its antibody candidates.
- Barzolvolimab Phase 3 chronic urticaria data readout expected
- FDA approval timeline for CDX-0159 drives valuation
- Cash burn raises secondary offering dilution risk
| Net Income: -309.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.36 > 0.02 and ΔFCF/TA -7.94 > 1.0 |
| NWC/Revenue: 539k% < 20% (prev 21.5k%; Δ 517k% < -1%) |
| CFO/TA -0.35 > 3% & CFO -252.0m > Net Income -309.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (78.5m) vs 12m ago 18.23% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.02% > 50% (prev 0.40%; Δ -0.38% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.84 (Total Current Assets 663.7m - Total Current Liabilities 60.5m) / Total Assets 721.5m |
| B: -2.83 (Retained Earnings -2.04b / Total Assets 721.5m) |
| C: -0.45 (EBIT TTM -309.1m / Avg Total Assets 685.0m) |
| D: 9.01 (Book Value of Equity 649.5m / Total Liabilities 72.1m) |
| Altman-Z'' = 2.69 = A |
| DSRI: 3.0 (Receivables 355k/90.0k, Revenue 112k/2.60m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.91 (AQ_t 0.05 / AQ_t-1 0.06) |
| SGI: 0.04 (Revenue 112k / 2.60m) |
| TATA: -0.08 (NI -309.1m - CFO -252.0m) / TA 721.5m) |
| Beneish M = -2.13 (Cap -4..+1) = BB |
As of November 18, 2026, the stock is trading at USD 28.04 with a total of 520,500 shares traded. Over the past week, the price has changed by -8.52%, over one month by -5.49%, over three months by -33.11% and over the past year by +7.85%.
Current recommended Stop Loss: 26.20 (which is 6.6% or 1.3 ATR below the current price).
Celldex Therapeutics has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy CLDX.
- StrongBuy: 12
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 64 | 128.2% |
P/S = 15236.744
P/B = 3.7805
Revenue TTM = 112k USD
EBIT TTM = -309.1m USD
EBITDA TTM = -305.4m USD
Long Term Debt = 8.43m USD (estimated: total debt 9.87m - short term 1.44m)
Short Term Debt = 1.44m USD (from shortTermDebt, last quarter)
Debt = 9.87m USD (from shortLongTermDebtTotal, last quarter) (leases 9.87m already included)
Net Debt = -640.4m USD (calculated: Debt 9.87m - CCE 650.3m)
Enterprise Value = 1.77b USD (2.41b + Debt 9.87m - CCE 650.3m)
Interest Coverage Ratio = unknown (Ebit TTM -309.1m / Interest Expense TTM 0.0)
EV/FCF = -6.81x (Enterprise Value 1.77b / FCF TTM -259.5m)
FCF Yield = -14.68% (FCF TTM -259.5m / Enterprise Value 1.77b)
FCF Margin = -232k% (FCF TTM -259.5m / Revenue TTM 112k)
Net Margin = -276k% (Net Income TTM -309.1m / Revenue TTM 112k)
Gross Margin = unknown ((Revenue TTM 112k - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.45 (Enterprise Value 1.77b / Total Assets 721.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.87m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -244.2m (EBIT -309.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.97 (Total Current Assets 663.7m / Total Current Liabilities 60.5m)
Debt / Equity = 0.02 (Debt 9.87m / totalStockholderEquity, last quarter 649.5m)
Debt / EBITDA = 2.10 (negative EBITDA) (Net Debt -640.4m / EBITDA -305.4m)
Debt / FCF = 2.47 (negative FCF - burning cash) (Net Debt -640.4m / FCF TTM -259.5m)
Total Stockholder Equity = 586.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -45.13% (Net Income -309.1m / Total Assets 721.5m)
RoE = -52.67% (Net Income TTM -309.1m / Total Stockholder Equity 586.9m)
RoCE = -51.93% (EBIT -309.1m / Capital Employed (Equity 586.9m + L.T.Debt 8.43m))
RoIC = -36.86% (negative operating profit) (NOPAT -244.2m / Invested Capital 662.4m)
WACC = 9.28% (E(2.41b)/V(2.42b) * Re(9.32%) + D(9.87m)/V(2.42b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.32% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.68 | Cagr: 8.02%
[DCF] Fair Price = unknown (Cash Flow -259.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.61 | # QB: 0
Revenue Correlation: -85.61 | Revenue CAGR: -78.58% | SUE: -0.76 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.97 | Chg30d=-6.65% | Revisions=+25% | Analysts=5
EPS current Year (2026-12-31): EPS=-4.02 | Chg30d=+2.56% | Revisions=+67% | GrowthEPS=-3.0% | GrowthRev=-11.1%
EPS next Year (2027-12-31): EPS=-4.19 | Chg30d=+1.00% | Revisions=-40% | GrowthEPS=-4.4% | GrowthRev=+382.1%
[Analyst] Revisions Ratio: +42% (up=7, down=2)